The claim checked

“DT120, an investigational 100 µg LSD formulation, produced superior anxiety outcomes to placebo in a Phase III GAD trial and therefore moved closer to possible FDA approval.”

What holds up

The reported Voyage design, enrollment of 214 adults, single 100 µg dose, 12-week follow-up, and -11.6 versus -6.2 HAM-A changes match Definium’s August 12, 2026 topline announcement. The trial registry independently confirms Voyage is a Phase III randomized, double-blind, placebo-controlled trial of DT120 in roughly 214 adults. Earlier Phase IIb evidence was published in JAMA and supports the claim that the candidate had previously shown promising anxiety results.

What does not

The post’s wording can sound closer to approval than the evidence warrants. A successful Phase III topline result does not establish FDA approval, long-term safety, or real-world effectiveness; the product remains investigational.

Why it matters

Not material enough to change the central takeaway because the post explicitly says another Phase III result is pending and frames FDA action as a future possibility rather than claiming approval.

Why Clear says this

The central message—that an LSD formulation achieved a meaningful late-stage clinical milestone for GAD and is closer to, but not approved by, the FDA—is supported. The main limitation is that the newest results are sponsor-reported topline data, so independent peer review and regulatory review remain outstanding.

Evidence

  • Definium’s August 12, 2026 announcement reports that Voyage met its primary endpoint: HAM-A change at week 12 was -11.6 with DT120 and -6.2 with placebo, a -5.4-point placebo-adjusted difference (p<0.0001).
  • The trial registry describes Voyage as a Phase III, randomized, double-blind, placebo-controlled, single-dose study with about 214 participants and an estimated completion in November 2026.
  • FDA states that Breakthrough Therapy designation is based on preliminary evidence and expedites development and review; it is not marketing approval.
  • A peer-reviewed JAMA Phase IIb randomized trial found dose-dependent anxiety reductions after a single lysergide dose, supporting the post’s account of earlier promise.

Sources used

1Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety DisorderEstablishes the sponsor-reported Phase III Voyage results, participant count, dosing, placebo comparison, onset, tolerability summary, and pending September Panorama readout.↗2UCSF Anxiety Trial: DT120 for Generalized Anxiety Disorder (Voyage)Independently confirms the registered Phase III Voyage study’s randomized, double-blind, placebo-controlled design, single-dose 12-week period, approximate enrollment, and investigational status.↗3FDA Fact Sheet: Breakthrough TherapiesEstablishes that Breakthrough Therapy designation reflects preliminary evidence and expedites development and review rather than granting approval.↗4Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical TrialEstablishes peer-reviewed Phase IIb evidence that a single lysergide dose produced dose-dependent anxiety reduction and informed Phase III dose selection.↗
Language: EnglishChecked 15 Aug 2026, 8:01 pmAI-assisted experiment · Sources remain the final authorityPermanent public research record · Corrections and removal requests supported